Ascendiant Capital Markets Forecasts Strong Price Appreciation for Atossa Therapeutics (NASDAQ:ATOS) Stock

Atossa Therapeutics (NASDAQ:ATOS - Free Report) had its price target increased by Ascendiant Capital Markets from $7.25 to $7.50 in a report released on Friday,Benzinga reports. They currently have a buy rating on the stock.

ATOS has been the topic of a number of other reports. Craig Hallum upgraded Atossa Therapeutics to a "strong-buy" rating and set a $4.00 price target on the stock in a report on Thursday. HC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of Atossa Therapeutics in a research report on Wednesday, March 26th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Atossa Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $6.17.

Atossa Therapeutics Stock Up 1.6%

NASDAQ:ATOS traded up $0.01 on Friday, hitting $0.91. The stock had a trading volume of 412,288 shares, compared to its average volume of 775,931. The business's fifty day moving average is $0.77 and its 200 day moving average is $0.86. The company has a market cap of $118.07 million, a PE ratio of -4.16 and a beta of 0.92. Atossa Therapeutics has a 52 week low of $0.55 and a 52 week high of $1.66.

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. Equities analysts predict that Atossa Therapeutics will post -0.22 earnings per share for the current fiscal year.

Institutional Trading of Atossa Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Nuveen LLC bought a new stake in shares of Atossa Therapeutics in the first quarter worth $115,000. Charles Schwab Investment Management Inc. grew its holdings in Atossa Therapeutics by 40.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 422,582 shares of the company's stock valued at $284,000 after purchasing an additional 120,934 shares during the period. Two Sigma Advisers LP grew its holdings in Atossa Therapeutics by 214.1% during the fourth quarter. Two Sigma Advisers LP now owns 42,400 shares of the company's stock valued at $40,000 after purchasing an additional 28,900 shares during the period. Millennium Management LLC bought a new stake in Atossa Therapeutics during the fourth quarter valued at about $28,000. Finally, Bank of America Corp DE grew its holdings in Atossa Therapeutics by 51.3% during the fourth quarter. Bank of America Corp DE now owns 111,475 shares of the company's stock valued at $105,000 after purchasing an additional 37,809 shares during the period. Institutional investors own 12.74% of the company's stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.